ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.33 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $49,832 | -79.5% | 12,184 | -21.1% | 0.00% | -100.0% |
Q1 2024 | $243,271 | +13.4% | 15,436 | +9.0% | 0.00% | 0.0% |
Q4 2023 | $214,554 | -12.2% | 14,162 | +16.2% | 0.00% | 0.0% |
Q3 2023 | $244,392 | -15.4% | 12,183 | +19.0% | 0.00% | 0.0% |
Q2 2023 | $288,786 | +33.3% | 10,237 | -4.9% | 0.00% | 0.0% |
Q4 2022 | $216,686 | -0.1% | 10,759 | +7.9% | 0.00% | 0.0% |
Q3 2022 | $217,000 | -11.4% | 9,968 | +14.1% | 0.00% | 0.0% |
Q2 2022 | $245,000 | -54.1% | 8,738 | -24.4% | 0.00% | 0.0% |
Q1 2022 | $534,000 | -55.7% | 11,556 | -19.5% | 0.00% | -50.0% |
Q4 2021 | $1,206,000 | +27.3% | 14,350 | +0.9% | 0.00% | -33.3% |
Q3 2021 | $947,000 | +10.9% | 14,218 | -11.4% | 0.00% | +50.0% |
Q2 2021 | $854,000 | +48.0% | 16,048 | +20.6% | 0.00% | 0.0% |
Q1 2021 | $577,000 | -12.0% | 13,303 | +5.3% | 0.00% | 0.0% |
Q4 2020 | $656,000 | – | 12,638 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Decheng Capital Management III (Cayman), LLC | 2,099,583 | $42,117,635 | 14.06% |
Mayo Clinic | 187,143 | $3,754,089 | 7.23% |
Matrix Capital Management Company, LP | 13,959,973 | $280,037,058 | 3.36% |
5AM Venture Management, LLC | 490,000 | $9,829,400 | 2.83% |
Eventide Asset Management | 7,814,039 | $156,749,622 | 2.82% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $19,287,410 | 2.70% |
Avidity Partners Management LP | 2,100,000 | $42,126,000 | 1.70% |
First Light Asset Management, LLC | 848,477 | $17,020,449 | 1.62% |
Sofinnova Investments, Inc. | 1,211,641 | $24,305,518 | 1.53% |
SECTORAL ASSET MANAGEMENT INC | 386,525 | $7,753,692 | 1.51% |